141 related articles for article (PubMed ID: 3779121)
1. [Cancer of the prostate: biologic bases for the use of an antiandrogen in its treatment].
Raynaud JP; Coussediere D; Moguilewsky M; Pottier J; Labrie F
Bull Cancer; 1986; 73(1):36-46. PubMed ID: 3779121
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer.
Moguilewsky M; Fiet J; Tournemine C; Raynaud JP
J Steroid Biochem; 1986 Jan; 24(1):139-46. PubMed ID: 3009970
[TBL] [Abstract][Full Text] [Related]
3. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological and clinical studies of the antiandrogen Anandron.
Moguilewsky M; Bertagna C; Hucher M
J Steroid Biochem; 1987; 27(4-6):871-5. PubMed ID: 3320565
[TBL] [Abstract][Full Text] [Related]
5. The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review.
Raynaud JP; Bonne C; Moguilewsky M; Lefebvre FA; Bélanger A; Labrie F
Prostate; 1984; 5(3):299-311. PubMed ID: 6374639
[TBL] [Abstract][Full Text] [Related]
6. Differential androgen modulation of AXC/SSh rat prostate cancer cell proliferation in vitro and its antagonism by antiandrogen.
Huot RI; Shain SA
Cancer Res; 1986 Aug; 46(8):3775-81. PubMed ID: 2942235
[TBL] [Abstract][Full Text] [Related]
7. Design of antiandrogens and their mechanisms of action: a case study (anandron).
Raynaud JP; Fiet J; Le Goff JM; Martin PM; Moguilewsky M; Ojasoo T
Horm Res; 1987; 28(2-4):230-41. PubMed ID: 3331376
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological studies on androgen suppression in therapy of prostate carcinoma.
Sandow J; von Rechenberg W; Engelbart K
Am J Clin Oncol; 1988; 11 Suppl 1():S6-10. PubMed ID: 3291602
[TBL] [Abstract][Full Text] [Related]
9. [Therapy of metastatic prostatic cancer by orchiectomy plus Anandron versus orchiectomy plus placebo. Initial results of a randomized multicenter study].
Knönagel H; Bolle JF; Hering F; Senn E; Hodel T; Neuenschwander H; Biedermann C
Helv Chir Acta; 1989 Aug; 56(3):343-5. PubMed ID: 2681086
[TBL] [Abstract][Full Text] [Related]
10. Changes in the androgen levels in the ventral prostate of spontaneously hypertensive rats after castration.
Hu M; Xin D; Chen J; Sun G; Wang Y; Na Y
BJU Int; 2009 Aug; 104(3):406-11. PubMed ID: 19239443
[TBL] [Abstract][Full Text] [Related]
11. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
12. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
Labrie F; Dupont A; Belanger A; Cusan L; Lacourciere Y; Monfette G; Laberge JG; Emond JP; Fazekas AT; Raynaud JP; Husson JM
Clin Invest Med; 1982; 5(4):267-75. PubMed ID: 6819101
[TBL] [Abstract][Full Text] [Related]
13. Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer.
Suzuki K; Nishiyama T; Hara N; Yamana K; Takahashi K; Labrie F
Prostate Cancer Prostatic Dis; 2007; 10(3):301-6. PubMed ID: 17387321
[TBL] [Abstract][Full Text] [Related]
14. Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer.
Geller J
Semin Oncol; 1985 Mar; 12(1 Suppl 1):28-35. PubMed ID: 3883502
[TBL] [Abstract][Full Text] [Related]
15. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
Joseph IB; Nelson JB; Denmeade SR; Isaacs JT
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2507-11. PubMed ID: 9815654
[TBL] [Abstract][Full Text] [Related]
16. New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonist.
Labrie F; Dupont A; Belanger A; Lefebvre FA; Cusan L; Raynaud JP; Husson JM; Fazekas AT
Horm Res; 1983; 18(1-3):18-27. PubMed ID: 6411578
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology and clinical studies with RU 23908 (Anandron).
Raynaud JP; Moguilewsky M; Tournemine C; Pottier J; Coussedière D; Salmon J; Husson JM; Bertagna C; Tremblay D; Pendyala L
Prog Clin Biol Res; 1985; 185A():99-120. PubMed ID: 4034583
[No Abstract] [Full Text] [Related]
18. The antiandrogen anandron potentiates the castrating effect of the LH-RH agonist buserelin in the rat.
Moguilewsky M; Tournemine C
Am J Clin Oncol; 1988; 11 Suppl 2():S148-51. PubMed ID: 3149454
[TBL] [Abstract][Full Text] [Related]
19. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
Nishiyama T; Hashimoto Y; Takahashi K
Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
[TBL] [Abstract][Full Text] [Related]
20. New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen.
Labrie F; Dupont A; Belanger A; Lefebvre FA; Cusan L; Monfette G; Laberge JG; Emond JP; Raynaud JP; Husson JM; Fazekas AT
J Steroid Biochem; 1983 Jul; 19(1C):999-1007. PubMed ID: 6411995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
